首页> 外文期刊>Advanced drug delivery reviews >Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity
【24h】

Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity

机译:结合抗原和免疫调节剂:针对自身免疫的抗原特异性免疫疗法的新兴趋势

获取原文
获取原文并翻译 | 示例
           

摘要

A majority of current therapies for autoimmune diseases are general immunosuppressants, which can compromise patient response to opportunistic infection and lead to adverse events. Using antigen-specific immunotherapy (ASIT) to selectively disarm autoimmune diseases, without suppressing the global immune response, would be a transformative therapy for patients. ASIT has been used historically in allergy hyposensitization therapy to induce tolerance to an allergen. Similar strategies to induce immune tolerance toward autoantigens responsible for autoimmune disease have been attempted but have yielded limited clinical success. Recent studies of ASIT for autoimmunity have explored combination therapy, combining the disease-causing autoantigen with an immunomodulatory compound. ASIT combination therapy may direct the immune response in an antigen-specific manner, potentially reversing the root cause of autoimmunity while limiting side effects. This review analyzes recent advances in ASIT applied to autoimmune diseases, emphasizing current combination therapies and future strategies. (C) 2015 Elsevier B.V. All rights reserved.
机译:当前用于自身免疫疾病的大多数疗法是一般的免疫抑制剂,其可损害患者对机会感染的反应并导致不良事件。使用抗原特异性免疫疗法(ASIT)选择性解除自身免疫性疾病的武装,而又不抑制整体免疫反应,对于患者而言将是一种转化疗法。 ASIT历史上已用于过敏性低敏治疗,以诱导对过敏原的耐受性。已经尝试了类似的策略来诱导针对负责自身免疫疾病的自身抗原的免疫耐受,但是在临床上取得的成功有限。针对自身免疫的ASIT的最新研究已经探索了组合疗法,将引起疾病的自身抗原与免疫调节化合物相结合。 ASIT联合疗法可能以抗原特异性方式指导免疫反应,可能逆转自身免疫的根本原因,同时限制副作用。这篇综述分析了应用于自身免疫性疾病的ASIT的最新进展,强调了当前的联合疗法和未来的策略。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号